RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Dove (grooming cosmetics)

Product
Developers: Unilever
Date of the premiere of the system: March 1957
Branches: Consumer goods,  Trade,  Pharmaceuticals, medicine, healthcare

2022: A cancer-provoking component was found in the product

On October 18, 2022, Unilever announced a voluntary recall of selected batches of aerosol dry shampoos produced before October 2021. Dove, Nexxus, Suave, TIGI (Rockaholic and Bed Head) and TRESemmé brands fell under the recall due to the potentially increased benzene content.

Benzene is classified as a carcinogen for humans. Exposure to benzene can occur by inhalation, orally and through the skin, and can lead to cancers, including leukemia and bone marrow cancer, as well as blood diseases that can be life-threatening. Benzene is ubiquitous in the environment. People around the world are exposed to it on a daily basis indoors and outdoors from numerous sources.

Dove

Based on the results of an independent health hazard assessment, daily exposure to benzene contained in recalled products at the level detected during testing should not lead to negative health effects. Unilever U.S. is recalling these products out of caution. Unilever has not received any reports of adverse events related to this recall as of October 2022.

The recalled products were distributed nationwide in the United States. Retailers have been notified to remove recalled products from store shelves. The full list of recalled products manufactured before October 2021 and consumer UPCs are provided below. This review does not affect any other Unilever product or brand.

An internal investigation found that the source was propellant, and Unilever is working with its propellant suppliers to resolve the issue. Consumers should stop using affected aerosol dry shampoos and visit the UnileverRecall.com website for instructions on how to obtain reimbursement for relevant products. If consumers have further questions, they can also contact Unilever U.S. by calling +1 (877) 270-7412. Adverse reactions or quality problems with this product can be reported to the FDA MedWatch Adverse Event Reporting Program via the Internet, regular mail, or fax.[1]

Notes